US.REGN · Regeneron Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.8383737761523204,
        "turnoverUsdM": 500.22900273011993,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.REGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 761.6414,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 5.7,
      "take_profit_price": 876.3907,
      "target_multiplier": 2.2,
      "technical_strength": 2.05,
      "take_profit_percent": 8.5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.4973362689959988,
    "stopLossPercent": 5.676747552304641,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 82.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 66.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 16
  },
  "market": {
    "ma20": 764.0615,
    "ma50": 790.7954,
    "close": 807.48,
    "prevClose": 782.04,
    "avgVolume20": 699455,
    "volumeRatio": 0.89,
    "changePercent": 3.25
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 16,
    "details": {
      "ret_5d": 0.07217970575738253,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 16,
      "vcp_bonus": 0,
      "vol_ratio": 0.8869046085126487,
      "ret_points": 12,
      "vol_points": 0,
      "range_ratio": 0.8132135048025623,
      "volat_points": 0,
      "day_range_pct": 0.02250209348843545,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 82.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 78,
        "contribution": 3.9
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 7.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 49.33,
        "contribution": 7.4
      },
      {
        "raw": 10,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 20.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69.33,
        "contribution": 20.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 66.3,
    "details": [
      "基本面分析總分: 3.9/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 7.4/15分",
      "催化劑分析: 10/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 20.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 10,
      "基本面": 3.9,
      "資金流": 13.2,
      "市場環境": 7.4,
      "情緒分析": 4,
      "技術信號": 20.8,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 10,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 2
            }
          },
          "catalystPoints": 10
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.4,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 500.22900273011993,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.REGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.44
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 739.87200315,
                "ma50": 726.61519988,
                "name": "QQQ",
                "close": 717.63,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.61649505,
                "ma50": 768.28659516,
                "name": "SPY",
                "close": 769.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.8383737761523204,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 4,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143009709,
                "url": "https://finnhub.io/api/news?id=353c95e3eda5abe619683dab99c8c2dfdb577a109a38ec01bc0a18658a2bb053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]",
                "category": "company",
                "datetime": 1792430807,
                "headline": "Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results"
              },
              {
                "id": 142923129,
                "url": "https://finnhub.io/api/news?id=fbc077e9a4ab3360613f77d02ffb0a458b5c50bd11e5f78d0ee990db60c52855",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new Phase III OPTIMA data showing Pasatru maintained efficacy out to 84 weeks in adults with FOP. The 84 week results indicate Pasatru prevented new bone formation and cut disease flare ups in treated fibrodysplasia ossificans progressiva patients. Regeneron flagged ongoing regulatory filings in additional markets and a planned pediatric trial to extend Pasatru access to younger FOP patients. The fresh 84 week Pasatru OPTIMA data fits into a...",
                "category": "company",
                "datetime": 1792106571,
                "headline": "Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment"
              },
              {
                "id": 142923128,
                "url": "https://finnhub.io/api/news?id=6056849c7398849ffaaba43b3a5224cefe4cf3f5320165469f11483915738003",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...",
                "category": "company",
                "datetime": 1792102318,
                "headline": "Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds"
              },
              {
                "id": 142922406,
                "url": "https://finnhub.io/api/news?id=4ffa5c67643f3f7ccd1d9525de13f5d50e42e3cf1e860f77de260493c5904254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in focus. With the stock closing at US$778.36 and investors watching new drug data closely, the open question is whether that price still lines up with what the business earns today. Over the past 5 years, Regeneron Pharmaceuticals has delivered a total return of 39.6%, which puts real pressure on the current earnings multiple to carry that...",
                "category": "company",
                "datetime": 1792098797,
                "headline": "Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data"
              },
              {
                "id": 142919465,
                "url": "https://finnhub.io/api/news?id=6d669b79661df8812954c57dd06722f00642e7563049c3867f581e787e864916",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and its peers.",
                "category": "company",
                "datetime": 1792075227,
                "headline": "Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks"
              },
              {
                "id": 142822890,
                "url": "https://finnhub.io/api/news?id=d457d42639a5330aff8fd807df942d1df29a462359879b2851d08c94f7fcfd4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The firm’s Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks.",
                "category": "company",
                "datetime": 1791826891,
                "headline": "Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month"
              },
              {
                "id": 142822892,
                "url": "https://finnhub.io/api/news?id=2467fd11a1c4475065f7fc6c9fb49c9d6c11d697e3d1ef205a5c8a91edcf78ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791817803,
                "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142669643,
                "url": "https://finnhub.io/api/news?id=b5b7584b61e45dbff0c5492423e05a0e19990f7ca8e1dfae0f3bd3d972491a37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments worth up to US$7.00 billion. These updates highlight Regeneron’s attempt to broaden its pipeline beyond current blockbusters, particularly through ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology...",
                "category": "company",
                "datetime": 1791324568,
                "headline": "Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)"
              }
            ],
            "raw_source": [
              {
                "id": 143029666,
                "url": "https://finnhub.io/api/news?id=788c530e9dc3d08eb03c8c51276a29b1f1b46179e627670424c650ecf6544433",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266868808/image_2266868808.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Parabilis Medicines, Inc. stock: speculative Buy on peptide platform, early zolu efficacy, Orphan/Fast Track, and strong cash runway. Click for this PBLS update.",
                "category": "company",
                "datetime": 1792502091,
                "headline": "Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free"
              },
              {
                "id": 143022488,
                "url": "https://finnhub.io/api/news?id=d9391795cb1cb4756518a26decb79a6ab1a95c9f284a69587d2d5fec01437beb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.",
                "category": "company",
                "datetime": 1792496257,
                "headline": "EyePoint halves workforce and ends Phase III trial early after endpoint miss"
              },
              {
                "id": 143009709,
                "url": "https://finnhub.io/api/news?id=353c95e3eda5abe619683dab99c8c2dfdb577a109a38ec01bc0a18658a2bb053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]",
                "category": "company",
                "datetime": 1792430807,
                "headline": "Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results"
              },
              {
                "id": 143009574,
                "url": "https://finnhub.io/api/news?id=8070bf91d38ecf0cb55fe6c532381fe54aad64d0db7dcf4b2a2b80d46cc14f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.",
                "category": "company",
                "datetime": 1792430174,
                "headline": "How Much Upside Is Left In Regeneron Stock?"
              },
              {
                "id": 143008459,
                "url": "https://finnhub.io/api/news?id=130b798a1309eaaf81df7a598d24115cd81a5e8f839659af63d4f8b2404064d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Is this company the biggest dark horse in the chronic weight management space?",
                "category": "company",
                "datetime": 1792421041,
                "headline": "Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market"
              },
              {
                "id": 143027184,
                "url": "https://finnhub.io/api/news?id=6e2e591b5f6ca6ae89d353c0f768b45915ace120986a65b3f4b328a013ee37a4",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Piper Sandler  analyst Biren Amin   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.",
                "category": "company",
                "datetime": 1792412614,
                "headline": "Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865"
              },
              {
                "id": 143006647,
                "url": "https://finnhub.io/api/news?id=3bb3aa6d830109503a48b217b40bc8978be07802ffb26afec43893d7a9143cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.",
                "category": "company",
                "datetime": 1792411800,
                "headline": "Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?"
              },
              {
                "id": 143000247,
                "url": "https://finnhub.io/api/news?id=caad6472ce665fb06df714f2b69df29b7626efe910c4543c093c572668429ba1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "MONTPELLIER, France & CAMBRIDGE, Mass., October 19, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (\"the Company\"), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced the appointment of Peter Weber, MD, MBA, as Chief Medical Officer, effective November 2, 2026.",
                "category": "company",
                "datetime": 1792398480,
                "headline": "Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer"
              },
              {
                "id": 142963192,
                "url": "https://finnhub.io/api/news?id=72476d04b1d43b4f80713712e58f62aa5de07856a666161f94f1b60a49c04ee2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron's biggest growth driver still has plenty of fuel left in the tank.",
                "category": "company",
                "datetime": 1792266240,
                "headline": "Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share"
              },
              {
                "id": 142944373,
                "url": "https://finnhub.io/api/news?id=191db45b67a3f22467adbc07b30d2592814754528dc1657344e3e775fa5623a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a well-tolerated first dose over 30 minutes, also recommended by CHMP TARRYTOWN, N.Y., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has",
                "category": "company",
                "datetime": 1792148400,
                "headline": "Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types"
              },
              {
                "id": 142945286,
                "url": "https://finnhub.io/api/news?id=f7ddf2b5e42e8137575d2fa4860426690df8734eb35bbc74528d746313bf876c",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a",
                "category": "company",
                "datetime": 1792134209,
                "headline": "Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications"
              },
              {
                "id": 142931419,
                "url": "https://finnhub.io/api/news?id=015a003ea7d295b3c3f35a4431963d7727eae52994b410cb65d924e7fa632317",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification lesions and flare ups. The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. This could reinforce...",
                "category": "company",
                "datetime": 1792128003,
                "headline": "Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?"
              },
              {
                "id": 142923129,
                "url": "https://finnhub.io/api/news?id=fbc077e9a4ab3360613f77d02ffb0a458b5c50bd11e5f78d0ee990db60c52855",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new Phase III OPTIMA data showing Pasatru maintained efficacy out to 84 weeks in adults with FOP. The 84 week results indicate Pasatru prevented new bone formation and cut disease flare ups in treated fibrodysplasia ossificans progressiva patients. Regeneron flagged ongoing regulatory filings in additional markets and a planned pediatric trial to extend Pasatru access to younger FOP patients. The fresh 84 week Pasatru OPTIMA data fits into a...",
                "category": "company",
                "datetime": 1792106571,
                "headline": "Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment"
              },
              {
                "id": 142923128,
                "url": "https://finnhub.io/api/news?id=6056849c7398849ffaaba43b3a5224cefe4cf3f5320165469f11483915738003",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...",
                "category": "company",
                "datetime": 1792102318,
                "headline": "Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds"
              },
              {
                "id": 142922406,
                "url": "https://finnhub.io/api/news?id=4ffa5c67643f3f7ccd1d9525de13f5d50e42e3cf1e860f77de260493c5904254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in focus. With the stock closing at US$778.36 and investors watching new drug data closely, the open question is whether that price still lines up with what the business earns today. Over the past 5 years, Regeneron Pharmaceuticals has delivered a total return of 39.6%, which puts real pressure on the current earnings multiple to carry that...",
                "category": "company",
                "datetime": 1792098797,
                "headline": "Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data"
              },
              {
                "id": 142922407,
                "url": "https://finnhub.io/api/news?id=17d9d1abaa5b4f3d1811e06a2cb5b3c698dc58b98a9e8312c279a436ed6007dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi has seen its share price under pressure over recent years, and a key issue for investors now is how well that current price lines up with what the business earns. The stock has declined 16.1% over the past 3 years, which raises a clear question about how the market is weighing Sanofi's earnings power against that weaker share performance. The expanded antibody alliance with Regeneron, including a US$1b upfront payment and potential milestones, may support expectations for future...",
                "category": "company",
                "datetime": 1792095455,
                "headline": "Sanofi (ENXTPA:SAN) Stock Looks Reasonable After Its Antibody Deal"
              },
              {
                "id": 142945287,
                "url": "https://finnhub.io/api/news?id=fbff90110983c2ac56d54285d727cd4b5dfbdb2cdddc7fa6e7a8277c6762212d",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "UBS  analyst Trung Huynh   upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.",
                "category": "company",
                "datetime": 1792084985,
                "headline": "UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978"
              },
              {
                "id": 142920358,
                "url": "https://finnhub.io/api/news?id=918812ff1a491e4ebac52dea4bab986d4f19b55f6b2fe5d94dd31c56facd2253",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.",
                "category": "company",
                "datetime": 1792078260,
                "headline": "Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?"
              },
              {
                "id": 142919465,
                "url": "https://finnhub.io/api/news?id=6d669b79661df8812954c57dd06722f00642e7563049c3867f581e787e864916",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and its peers.",
                "category": "company",
                "datetime": 1792075227,
                "headline": "Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks"
              },
              {
                "id": 142919466,
                "url": "https://finnhub.io/api/news?id=4d77f68f77e59b82a8c703f1974110be80dc420c7f7c8582396cf8b721a193ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.",
                "category": "company",
                "datetime": 1792073040,
                "headline": "Here's Why You Should Add EYPT Stock to Your Portfolio Now"
              },
              {
                "id": 142921522,
                "url": "https://finnhub.io/api/news?id=21d5d52ed70d99e7f05736b16d00e5d4c77c37cf1abd9f2266d13ba6af168c31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.",
                "category": "company",
                "datetime": 1792068990,
                "headline": "What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report"
              },
              {
                "id": 142913684,
                "url": "https://finnhub.io/api/news?id=24216ce278600124de9e90b6ea830cf3a494fd282df6011d3f1cd37a0fdabd81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Pre-Market Stock Futures: Futures are trading mixed, but the Nasdaq is down sharply Thursday morning as worries about AI overspending continue to emerge. Wall Street’s worst fears materialized yesterday, as the Consumer Price Index (CPI) report came in above expectations, with energy prices as a major factor. This will, of course, change the narrative on […]",
                "category": "company",
                "datetime": 1792066211,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142887864,
                "url": "https://finnhub.io/api/news?id=199e7ff21910db9e131ac0f301decd1fbb6d88573e68f3239632a2555275ba9c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249501702/image_2249501702.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Read more here.",
                "category": "company",
                "datetime": 1791995220,
                "headline": "Longleaf Partners Global Fund Q3 2026 Portfolio Review"
              },
              {
                "id": 142886457,
                "url": "https://finnhub.io/api/news?id=495209183eea6d7318d1d4db2134daf72888cf50b52194a8d8bf4877687ca229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.",
                "category": "company",
                "datetime": 1791990540,
                "headline": "Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?"
              },
              {
                "id": 142881756,
                "url": "https://finnhub.io/api/news?id=a3f2fab0fe8cf0c3c08140592360ce9c537164de8862f41573d4d377aedba88f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.",
                "category": "company",
                "datetime": 1791977440,
                "headline": "Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight"
              },
              {
                "id": 142879309,
                "url": "https://finnhub.io/api/news?id=3d81aef4afb7edd2d60e3c81f1f561bc77f0f09163647dc78f5bc8452a6df2dd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260474979/image_2260474979.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "The market is regaining confidence in Avantor’s ability to grow organically and in Emmanuel Ligner’s turnaround plan.",
                "category": "company",
                "datetime": 1791961320,
                "headline": "Longleaf Partners Fund Q3 2026 Portfolio Review"
              },
              {
                "id": 142848664,
                "url": "https://finnhub.io/api/news?id=d6cc5a18341120b4042d9c7782d95ce246363cae42d5930c60a8044f46d2e33f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.",
                "category": "company",
                "datetime": 1791892852,
                "headline": "Why A Biotech M&A Wave May Hit This Winter"
              },
              {
                "id": 142847595,
                "url": "https://finnhub.io/api/news?id=08b7af3fc403da7b33bf4caa37f8c24d79b7e441c76506d5e0a00d60781d5931",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The trial showed that Pasatru prevented new heterotopic ossification lesions, compared to nine in the placebo cohort.",
                "category": "company",
                "datetime": 1791889237,
                "headline": "Regeneron reports 84-week Phase III data for Pasatru in adult FOP"
              },
              {
                "id": 142822890,
                "url": "https://finnhub.io/api/news?id=d457d42639a5330aff8fd807df942d1df29a462359879b2851d08c94f7fcfd4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The firm’s Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks.",
                "category": "company",
                "datetime": 1791826891,
                "headline": "Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month"
              },
              {
                "id": 142822225,
                "url": "https://finnhub.io/api/news?id=aa9e4c8a2b6d82815ed32d4c2f7a81ce11c4a5cf84eb068cff96ca2163909ff0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1791822901,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 142822891,
                "url": "https://finnhub.io/api/news?id=c8428d11cc855ad37b8e56192877e0955d9577d176ea106fa964da984d7530de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week re",
                "category": "company",
                "datetime": 1791821160,
                "headline": "Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension"
              },
              {
                "id": 142822892,
                "url": "https://finnhub.io/api/news?id=2467fd11a1c4475065f7fc6c9fb49c9d6c11d697e3d1ef205a5c8a91edcf78ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791817803,
                "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142850662,
                "url": "https://finnhub.io/api/news?id=4867410b29e49128d19cce274da8f622f3f139ecd6897d070857b50a22ffed0a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Female-Doctor-And-Patient-Reviewing-And-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.",
                "category": "company",
                "datetime": 1791812098,
                "headline": "Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth"
              },
              {
                "id": 142822447,
                "url": "https://finnhub.io/api/news?id=32f44f091b7278456647332f1e9e50dae6fde9e2e8c0875b9c7b690591abf9e4",
                "image": "https://image.cnbcfm.com/api/v1/image/108399068-17918243181791824315-48955904303-1080pnbcnews.jpg?v=1791824317&w=1920&h=1080",
                "source": "CNBC",
                "related": "REGN",
                "summary": "The Investment Committee debate the latest Calls of the Day.",
                "category": "company",
                "datetime": 1791811482,
                "headline": "Calls of the Day: Adobe, eBay and Regeneron"
              },
              {
                "id": 142850663,
                "url": "https://finnhub.io/api/news?id=d12ac31a0b3f52bee3d9d7dff72f0ac812603f16c0b279045890a86966ee336a",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).",
                "category": "company",
                "datetime": 1791807041,
                "headline": "Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions"
              },
              {
                "id": 142764205,
                "url": "https://finnhub.io/api/news?id=78f2a1b20a92c2f2664cbf93a4df03d907ffde640be59eabf97e4f652329c59c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.",
                "category": "company",
                "datetime": 1791560209,
                "headline": "Is Vertex Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142731005,
                "url": "https://finnhub.io/api/news?id=a03af81e05622affeece7ada4b73724789bfecb2216ca926f6f57869d134b6ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.",
                "category": "company",
                "datetime": 1791472860,
                "headline": "Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD"
              },
              {
                "id": 142762667,
                "url": "https://finnhub.io/api/news?id=0a42387c82869f823c2f72eecec07dd0d688131be767dcd63a27b1094bbbfe35",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.",
                "category": "company",
                "datetime": 1791454144,
                "headline": "RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810"
              },
              {
                "id": 142715505,
                "url": "https://finnhub.io/api/news?id=182fb978defe32667d9f8fa673fb3384f4475ff84a07e1437b8421ca07686da0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven’s next-generation TROP2-directed ADC BHV-1510, deepening Regeneron’s involvement across Biohaven’s oncology...",
                "category": "company",
                "datetime": 1791440284,
                "headline": "Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?"
              },
              {
                "id": 142730012,
                "url": "https://finnhub.io/api/news?id=30ae98d605d0a137f63dd0df6cda3489a1f0dc7ea54a95872b772dce21c3d7de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "George Yancopoulos, Regeneron chief executive and scientific officer, shares the difference between how his company invests compared to their competitors, the importance of data for finding the next breakthrough drug and how to out-innovate China.",
                "category": "company",
                "datetime": 1791402120,
                "headline": "Regeneron CEO on R&D, Data and Omics"
              },
              {
                "id": 142726874,
                "url": "https://finnhub.io/api/news?id=58b1696653aebc7a33b6ee167a256c59544d32bd737bd85923d9b64dfa5a6072",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.",
                "category": "company",
                "datetime": 1791378355,
                "headline": "Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780"
              },
              {
                "id": 142726875,
                "url": "https://finnhub.io/api/news?id=60ed2097a6ad37ac86a370148e19b21a8516d7fd644f3b65c5e75acbe838c4af",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.",
                "category": "company",
                "datetime": 1791370533,
                "headline": "Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779"
              },
              {
                "id": 142669643,
                "url": "https://finnhub.io/api/news?id=b5b7584b61e45dbff0c5492423e05a0e19990f7ca8e1dfae0f3bd3d972491a37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments worth up to US$7.00 billion. These updates highlight Regeneron’s attempt to broaden its pipeline beyond current blockbusters, particularly through ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology...",
                "category": "company",
                "datetime": 1791324568,
                "headline": "Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)"
              },
              {
                "id": 142667430,
                "url": "https://finnhub.io/api/news?id=8995a666ebf6b720d179c49695be772306a09407553d20fd984dd6644bc12b96",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2239308472/image_2239308472.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Click for more on GMAB stock.",
                "category": "company",
                "datetime": 1791299158,
                "headline": "Genmab: Epkinly Shines In Phase 3 DLBCL Trial"
              },
              {
                "id": 142662121,
                "url": "https://finnhub.io/api/news?id=1814947a413ad5ba3289f5ef1fe4b390be7047565b6c1ab53993b45fb9fd992e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants TARRYTOWN, N.Y., Oct. 06, 20",
                "category": "company",
                "datetime": 1791284400,
                "headline": "Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026"
              },
              {
                "id": 142695316,
                "url": "https://finnhub.io/api/news?id=1697eb892a56483ea4cbedc938fa73b870be2ae883bd9e0641640d8f0554ec76",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "JP Morgan  analyst Chris Schott   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.",
                "category": "company",
                "datetime": 1791284109,
                "headline": "JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950"
              },
              {
                "id": 142664591,
                "url": "https://finnhub.io/api/news?id=12bfcc5fbcc08f5df4917d19240da02579de46ecc8a2ac3d353ee35bd139f6c1",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm",
                "category": "company",
                "datetime": 1791273492,
                "headline": "Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M"
              },
              {
                "id": 142662618,
                "url": "https://finnhub.io/api/news?id=d78ffd39021735e4739cfbbd4e7ce2c89bcdbad94ff4f003fc44637d8d221831",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/Nasdaq-Inscription-Next-To-Us-Dollars--T.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.",
                "category": "company",
                "datetime": 1791212429,
                "headline": "Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average"
              },
              {
                "id": 142623247,
                "url": "https://finnhub.io/api/news?id=ba7b196a483297c9f1b8ca87079d6a983e9dca546f3adb036626872911e86b0c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277380647/image_1277380647.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron downgraded to Hold as shares near DCF value; DUPIXENT growth, EYLEA HD outlook, R&D risks, and key catalysts. Click for more on REGN stock.",
                "category": "company",
                "datetime": 1791101705,
                "headline": "Regeneron: The Easy Money Has Been Made (Rating Downgrade)"
              },
              {
                "id": 142600044,
                "url": "https://finnhub.io/api/news?id=1510dab33932c078bbdfa82bd31981132c1fe6efe647aba58030c1ffd02f120c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]",
                "category": "company",
                "datetime": 1790995209,
                "headline": "Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets"
              },
              {
                "id": 142596125,
                "url": "https://finnhub.io/api/news?id=91306fa3d9deb441f4497b6d7a76a19ba222c2b00e2a72e156a56807caad6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.",
                "category": "company",
                "datetime": 1790986415,
                "headline": "Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals"
              },
              {
                "id": 142596129,
                "url": "https://finnhub.io/api/news?id=9a86f42c45df4b219625df3ae09d1f8c869286517c269711a967d04fa0ee984a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.",
                "category": "company",
                "datetime": 1790965283,
                "headline": "An $8 Billion Reason Why Regeneron Stock Is in Focus"
              },
              {
                "id": 142591003,
                "url": "https://finnhub.io/api/news?id=1830d9d76e845d0d4bbeb3ad349b1a24d8bc75f660a49370215a3098ecd25187",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.",
                "category": "company",
                "datetime": 1790953200,
                "headline": "This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking"
              },
              {
                "id": 142614227,
                "url": "https://finnhub.io/api/news?id=eb455a7439e0cfb867ce4e6f1a89b656a918ebdf13e5064bcc5cfee9b845e1f6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Brazil--So-Paulo--October-12-2020-Man-Ho.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.",
                "category": "company",
                "datetime": 1790947151,
                "headline": "Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data"
              },
              {
                "id": 142588607,
                "url": "https://finnhub.io/api/news?id=9d6f6c9b9cba60e13bdd08f243bca8a8f626689cd8f95d3ee8087b2fed3d5bc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.",
                "category": "company",
                "datetime": 1790945100,
                "headline": "Sanofi, Regeneron Expand Immunology Alliance With New Antibodies"
              },
              {
                "id": 142588608,
                "url": "https://finnhub.io/api/news?id=4790079739a8bd792e944150efd84d8b0c4202175afb2b77a959309599bb90c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron will receive $1 billion upfront, with up to $7 billion more in milestones, to co-develop four next-generation antibody drug candidates",
                "category": "company",
                "datetime": 1790944016,
                "headline": "Sanofi pays Regeneron up to $8B to expand immunology alliance"
              },
              {
                "id": 142563799,
                "url": "https://finnhub.io/api/news?id=33db27cdedbadf5d64a8a23a56996eefb15a99869c55975888b7930bc6d25e12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...",
                "category": "company",
                "datetime": 1790892442,
                "headline": "Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks"
              },
              {
                "id": 142563863,
                "url": "https://finnhub.io/api/news?id=137655fb1896bb5a7e64b2dec7d81f9bf72a15c7f2adce1061ce996979781ad1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology alliance with Sanofi on terms that left economics for its blockbuster drug Dupixent untouched.",
                "category": "company",
                "datetime": 1790892307,
                "headline": "Why Regeneron (REGN) Stock Is Trading Lower Today"
              },
              {
                "id": 142562991,
                "url": "https://finnhub.io/api/news?id=d87e788f494f1754d63aeac50d405e033c0ecb2363c9d315f9e2a391f0a26909",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.",
                "category": "company",
                "datetime": 1790890501,
                "headline": "OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD"
              },
              {
                "id": 142560293,
                "url": "https://finnhub.io/api/news?id=b20e08d06594043d73774dff90800dc69a3fc3d1ae58095ba1758b392220c4e2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1790872502,
                "headline": "Which S&P500 stocks are moving on Thursday?"
              },
              {
                "id": 142561864,
                "url": "https://finnhub.io/api/news?id=438f031b70884b7af7b05e66c23608f1ec564f2f2b74036e5797ca13100b415b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies October 1, 2026 8:00 AM...",
                "category": "company",
                "datetime": 1790869824,
                "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript"
              },
              {
                "id": 142561002,
                "url": "https://finnhub.io/api/news?id=459b38f08870664db4209c6e9f7e4b6c4acb27a76db4576a4f703c107a9113aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.",
                "category": "company",
                "datetime": 1790869080,
                "headline": "Sanofi, Regeneron broaden alliance to find their next Dupixent"
              },
              {
                "id": 142559929,
                "url": "https://finnhub.io/api/news?id=8da993d57d1202f729f59f85cb16d2268b7e6d43249b6d82a626bb0c697965fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will ad",
                "category": "company",
                "datetime": 1790868900,
                "headline": "Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)"
              },
              {
                "id": 142559930,
                "url": "https://finnhub.io/api/news?id=b6d305bbb5a86a2253e76142744d0dc88c27a0cd47488254681b7b1f5c91570b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharm",
                "category": "company",
                "datetime": 1790868600,
                "headline": "Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss"
              },
              {
                "id": 142590895,
                "url": "https://finnhub.io/api/news?id=beaa73eeaab8ef8710d4cae4c7be1d0069e500e0922f5875a6ae84ed476aff67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.",
                "category": "company",
                "datetime": 1790866999,
                "headline": "Pfizer’s eczema drug clears skin in mid-stage trial"
              },
              {
                "id": 142559931,
                "url": "https://finnhub.io/api/news?id=d7b742b87b2599e1e87ba40ec832e6ed41a5f36f7c907e9915a6ac9d774b2015",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew",
                "category": "company",
                "datetime": 1790866922,
                "headline": "Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion"
              },
              {
                "id": 142562992,
                "url": "https://finnhub.io/api/news?id=6aa475753c3c1792e30240984055cb48fecea53f3ed48168afcccaaf598e2e15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.",
                "category": "company",
                "datetime": 1790866656,
                "headline": "Kodiak Sciences More Than Doubles on Eye Disease Trial Results"
              },
              {
                "id": 142588280,
                "url": "https://finnhub.io/api/news?id=1b36f0d2670d8739c14ad84b819c0165eb5095267d692cb524a15e5c181de3c7",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Jefferies  analyst Akash Tewari   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.",
                "category": "company",
                "datetime": 1790864788,
                "headline": "Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930"
              },
              {
                "id": 142559752,
                "url": "https://finnhub.io/api/news?id=b3b28209e464692e8ba83a15baee237f46fc99ac614d21c1995244ce69f32e9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu",
                "category": "company",
                "datetime": 1790863439,
                "headline": "Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion"
              },
              {
                "id": 142557740,
                "url": "https://finnhub.io/api/news?id=5d5953131721a88f722b7a6e427349b870531e20af1c034150db5bb9a35e2726",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1790861886,
                "headline": "Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 142560597,
                "url": "https://finnhub.io/api/news?id=26f7032aba1266a905c4dfd11a725fa060f8b98d79d3b5c820bfc4664cff3528",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1152284409/image_1152284409.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron and Sanofi expand antibody pact targeting IL-4/IL-13 inflammation therapies, with $1B upfront and up to $7B milestones. Click to read my analysis for more.",
                "category": "company",
                "datetime": 1790861390,
                "headline": "Regeneron And Sanofi Announce A Win-Win Collaboration Expansion"
              },
              {
                "id": 142557733,
                "url": "https://finnhub.io/api/news?id=884d4eb42507bdd7297f3abee12f004467d90d4f489091c768d42a4d510f4394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.",
                "category": "company",
                "datetime": 1790858880,
                "headline": "Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win"
              },
              {
                "id": 142588276,
                "url": "https://finnhub.io/api/news?id=98405978976ec3cdfb0485d076c032af8fde2cace6efed15919e831a0748ef93",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/01/United-Therapeutics.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.",
                "category": "company",
                "datetime": 1790855391,
                "headline": "This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday"
              },
              {
                "id": 142556721,
                "url": "https://finnhub.io/api/news?id=5bf10cfe4a708030512458c6f0f4e39140407b3ff3baa7b11dfc5725df0ca842",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.",
                "category": "company",
                "datetime": 1790854858,
                "headline": "Sanofi and Regeneron expand immunology partnership to the tune of $8bn"
              },
              {
                "id": 142588282,
                "url": "https://finnhub.io/api/news?id=7db04c51d2af4e184d0a77f3021ff2fea5c375a99d75d35091b160287a691eb7",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss during",
                "category": "company",
                "datetime": 1790854635,
                "headline": "Regeneron Pharmaceuticals Announces Its Results From Phase 2 COURAGE Study Of Trevogrumab Shows 70% Prevention Of Muscle Loss Associated With Semaglutide Treatment; Lower Dose Of Trevogrumab Did Not Enhance Weight Loss Achieved With Semaglutide Alone"
              },
              {
                "id": 142556722,
                "url": "https://finnhub.io/api/news?id=4a21d8d6874e5216d69b810c6f697fbb5f2f43ced97adf9e49dab37f2a54ac1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.",
                "category": "company",
                "datetime": 1790854614,
                "headline": "Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights"
              },
              {
                "id": 142588283,
                "url": "https://finnhub.io/api/news?id=948fad5150af81bbb3fafe8e89714df66f36c5bfc1c05b5bad8837ae2cdbc498",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/01/Regeneron.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment and new clinical trials.",
                "category": "company",
                "datetime": 1790852856,
                "headline": "Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion"
              },
              {
                "id": 142559279,
                "url": "https://finnhub.io/api/news?id=f4c8f20466148c25f99b16c17ab875ab2d5f46fa31e141c58d28c8280b2f78c4",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "2026-10-01. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
                "category": "company",
                "datetime": 1790851867,
                "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow"
              },
              {
                "id": 142557452,
                "url": "https://finnhub.io/api/news?id=e22bb3916b8c1f363307d06724808d4e7ae4fd356ef2f67ad8ffe9d035413dbb",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "https://edge.media-server.com/mmc/p/dfer26i6/",
                "category": "company",
                "datetime": 1790844670,
                "headline": "Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal"
              },
              {
                "id": 142557453,
                "url": "https://finnhub.io/api/news?id=953561930cbe067f0d27430aa1e99b279c2a83fd0c1e84da8576f11504083aa5",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Argus Research  analyst Jasper Hellweg   upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.",
                "category": "company",
                "datetime": 1790844017,
                "headline": "Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target"
              },
              {
                "id": 142557928,
                "url": "https://finnhub.io/api/news?id=3beb0ba346afc65d3af9cd7478252162fa3d61180307e8803ebd021e9e0f3c79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.",
                "category": "company",
                "datetime": 1790836020,
                "headline": "Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion"
              },
              {
                "id": 142536799,
                "url": "https://finnhub.io/api/news?id=93c42a34ba436a3fc389924ba315cc8810e4ef178dee2553f3bb7040b21260f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.",
                "category": "company",
                "datetime": 1790834428,
                "headline": "Sanofi, Regeneron expand partnership in deal worth up to $8 billion"
              },
              {
                "id": 142532611,
                "url": "https://finnhub.io/api/news?id=91f44dfa20404df1fe5fb24411d902e3a15dba9ffb6af5c6659aefe1e25f76b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev",
                "category": "company",
                "datetime": 1790830800,
                "headline": "Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies"
              },
              {
                "id": 142532610,
                "url": "https://finnhub.io/api/news?id=b128e51db6ca424d884fcf4761d83bb1142a6dcc079670bd80596b4f377b189c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference",
                "category": "company",
                "datetime": 1790830800,
                "headline": "Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies"
              },
              {
                "id": 142557454,
                "url": "https://finnhub.io/api/news?id=9c2c1c696fdee4834f1c144532569d3a93ca054130c742e56d5aa4c8ff6e8af1",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical",
                "category": "company",
                "datetime": 1790819322,
                "headline": "Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally"
              },
              {
                "id": 142524132,
                "url": "https://finnhub.io/api/news?id=99b644c4dbe7656e77f51ec70027d88d044f33bbf2754173679e66718fbea76e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.",
                "category": "company",
                "datetime": 1790802073,
                "headline": "Why Moderna (MRNA) Shares Are Falling Today"
              },
              {
                "id": 142530199,
                "url": "https://finnhub.io/api/news?id=2e2d6f9e88c3b166b392e28c77871880c87b2f2ccc130062ab3138f10abf5510",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.",
                "category": "company",
                "datetime": 1790800857,
                "headline": "This Analyst Just Downgraded Moderna Stock. Here's Why."
              },
              {
                "id": 142514580,
                "url": "https://finnhub.io/api/news?id=67a0638a9dc70a36cc523d826ed8db23bc2b76d01e9bf1d3652b900408810d84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.",
                "category": "company",
                "datetime": 1790769905,
                "headline": "A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?"
              },
              {
                "id": 142516123,
                "url": "https://finnhub.io/api/news?id=56f0c9ece7c01ec1810bcdd9f0956f5945caa2a7ec838f66a7edb7e950e41596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.",
                "category": "company",
                "datetime": 1790769808,
                "headline": "MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum"
              },
              {
                "id": 142498361,
                "url": "https://finnhub.io/api/news?id=bdcfcfc06de86328a7f733848b6543e114871488323f76d1929944a21cef51c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1790692803,
                "headline": "REGN or ILMN: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142498360,
                "url": "https://finnhub.io/api/news?id=f8f0ef3b7ae045a84bc7a7c12bf0637dbe6ffe580a37944fe31ba661cb54c3d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.",
                "category": "company",
                "datetime": 1790691180,
                "headline": "KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears"
              },
              {
                "id": 142498169,
                "url": "https://finnhub.io/api/news?id=d2c572d44e49348936f806a412fea8be14cb17d57fc6724e04ef1541374fc90d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Demy-Colton today announced the agenda for BioFuture™ 2026, taking place October 27–28 at Cure, 345 Park Avenue South in New York City. The conference will bring together leaders from across biopharma, healthcare, investment, technology and policy for discussions, company presentations, networking and one-to-one partnering, followed by virtual partnering November 3–5.",
                "category": "company",
                "datetime": 1790690400,
                "headline": "BioFuture 2026 Convenes Industry Leaders in New York City to Explore the Trends Reshaping Biopharma and Healthcare"
              },
              {
                "id": 142498363,
                "url": "https://finnhub.io/api/news?id=83c7d7593dca13e798bf2cba735404e9f07452352cce8fc8b53a5e435a71f3cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.",
                "category": "company",
                "datetime": 1790688000,
                "headline": "Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV"
              },
              {
                "id": 142498364,
                "url": "https://finnhub.io/api/news?id=e661587fde34db46491ed31cc9e575890b7b4be2158ecdcf53879ce09ff6b3a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.",
                "category": "company",
                "datetime": 1790687820,
                "headline": "KROS Begins Dosing in Phase II Study With Rinvatercept in DMD"
              },
              {
                "id": 142496115,
                "url": "https://finnhub.io/api/news?id=afce856686cb0927957fded63bfa72ded51017f00ab8ee4bd82c7967298d0b14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.",
                "category": "company",
                "datetime": 1790681820,
                "headline": "GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?"
              },
              {
                "id": 142489118,
                "url": "https://finnhub.io/api/news?id=7018a9aa5a96034dbd5d411f283bb9cd36ec08d58e28aa0190756627ee827efb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...",
                "category": "company",
                "datetime": 1790672823,
                "headline": "Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?"
              },
              {
                "id": 142496858,
                "url": "https://finnhub.io/api/news?id=bbca73a12c300074712c8beb502d93fdb3b80add792b134e4a9c31ca9408d73b",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "RBC Capital  analyst Brian Abrahams   reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and maintains $737 price target.",
                "category": "company",
                "datetime": 1790670913,
                "headline": "RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $737 Price Target"
              },
              {
                "id": 142493778,
                "url": "https://finnhub.io/api/news?id=0b2f7f810f70395a2cacb2e0d08118903ac1ac743984c1905bf6998b3ab15787",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237482641/image_2237482641.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.",
                "category": "company",
                "datetime": 1790667020,
                "headline": "Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress"
              },
              {
                "id": 142483453,
                "url": "https://finnhub.io/api/news?id=244469275938bed2a3f8980cfd5fdcdca279638480c00ae887cfb764771d02b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...",
                "category": "company",
                "datetime": 1790665685,
                "headline": "What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?"
              },
              {
                "id": 142500524,
                "url": "https://finnhub.io/api/news?id=6d48fb917575c82e6b55a4a549d8317be9540d4e816bbdfba1b9f272c36c43ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.",
                "category": "company",
                "datetime": 1790654460,
                "headline": "New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs"
              },
              {
                "id": 142474585,
                "url": "https://finnhub.io/api/news?id=4715130fe3581087d4f441156f06e81cb40102f0f592ddc333aef6aff0578a09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.",
                "category": "company",
                "datetime": 1790647980,
                "headline": "KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’"
              },
              {
                "id": 142469092,
                "url": "https://finnhub.io/api/news?id=fcd57ca225825364ca6e426cdf79ccc9dc0328c9d9b3727af525ef34e59c00f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The healthcare company will release its third-quarter results next month.",
                "category": "company",
                "datetime": 1790616301,
                "headline": "Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?"
              },
              {
                "id": 142469327,
                "url": "https://finnhub.io/api/news?id=b576f610d96405b931a94698596349fbd16fed37ad8bd783c27d08c480bdd2e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.",
                "category": "company",
                "datetime": 1790615738,
                "headline": "OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs"
              },
              {
                "id": 142469328,
                "url": "https://finnhub.io/api/news?id=a1ee4444bc7448674b3e841baa4cf92b01f8114eab6b099017feb03c0ec1660e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.",
                "category": "company",
                "datetime": 1790612460,
                "headline": "Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%"
              },
              {
                "id": 142469326,
                "url": "https://finnhub.io/api/news?id=6576ad23bafaed889c00ee39991c9982ab0fcb1d0d8f26c375245afe1ed63dd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.",
                "category": "company",
                "datetime": 1790611860,
                "headline": "Kodiak skyrockets on positive study data for 2 eye drugs"
              },
              {
                "id": 142469329,
                "url": "https://finnhub.io/api/news?id=33d7ad9b8ed8e9a5252819e5eae3d2f6cac1151bfa9ad5c06ed7dab7b177a834",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.",
                "category": "company",
                "datetime": 1790611755,
                "headline": "Kodiak’s stock rallies on Phase III wAMD success"
              },
              {
                "id": 142468359,
                "url": "https://finnhub.io/api/news?id=02ceaf1f5fe3a661f54a1c8f6d68cbec2b057d781457de79a2ee533495f9dd21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1790608716,
                "headline": "1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm"
              },
              {
                "id": 142468360,
                "url": "https://finnhub.io/api/news?id=093354583ce44fd78f370f143020d11cef3d075a2263ebea0cb0fd0c28b6fa03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.",
                "category": "company",
                "datetime": 1790606340,
                "headline": "Kodiak Sciences Stock Surges 156% After Eye-Disease Drugs Pass Key Trial"
              },
              {
                "id": 142466497,
                "url": "https://finnhub.io/api/news?id=5a71cb258982d4a0d2d0ada48b002cac090c188d4c7c46c7605304ae726ca556",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.",
                "category": "company",
                "datetime": 1790603922,
                "headline": "Why This Regeneron Eye Rival Just Catapulted More Than 120%"
              },
              {
                "id": 142465017,
                "url": "https://finnhub.io/api/news?id=96528866f06126a4dccf66a1d697241350195cb7ab682fcee3971b78629c8a9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.",
                "category": "company",
                "datetime": 1790600635,
                "headline": "Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus"
              },
              {
                "id": 142465019,
                "url": "https://finnhub.io/api/news?id=5ccc96958948303f3ebe778c27f06e16375a6d2125a6ca030aabfaf6a769fd33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.",
                "category": "company",
                "datetime": 1790596680,
                "headline": "Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial"
              },
              {
                "id": 142463870,
                "url": "https://finnhub.io/api/news?id=9718abe44ed044b937428a509a26ab5544acd5acdfb87a771a01c6c8f1dcdd25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biohaven Ltd. (NYSE: BHVN) (\"Biohaven\"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 202",
                "category": "company",
                "datetime": 1790595000,
                "headline": "Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026"
              },
              {
                "id": 142495576,
                "url": "https://finnhub.io/api/news?id=e6018e0402acd14ea66fa0e1a9efa674957e612a1c682de47d824b1b99fe2741",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Regeneron.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.",
                "category": "company",
                "datetime": 1790594224,
                "headline": "Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug"
              },
              {
                "id": 142467360,
                "url": "https://finnhub.io/api/news?id=aab412b5ba75bab4420d612136e10533d3a0237b0a747681860c52934ea3b23f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Macro-Studio-Expression-Shot-Of-Womans-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.",
                "category": "company",
                "datetime": 1790589922,
                "headline": "Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine"
              },
              {
                "id": 142423855,
                "url": "https://finnhub.io/api/news?id=4c71243a51db5b8d130215e9973ad233fdca8ce6909d0974cab8345089d4ab70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.",
                "category": "company",
                "datetime": 1790343000,
                "headline": "Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent"
              },
              {
                "id": 142386895,
                "url": "https://finnhub.io/api/news?id=710607f187d2745a2ee1c8c86fc9867276c48ff7fb564f016104f751e9f2ba75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call InformationParticipants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s websi",
                "category": "company",
                "datetime": 1790280300,
                "headline": "Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026"
              },
              {
                "id": 142380695,
                "url": "https://finnhub.io/api/news?id=95cbc4d4169ea81561c92380d3259a53d2c97cdcafa7b283872169a84624ee5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has delivered a strong share price run over the past year, which puts a spotlight on whether the current US$801.82 level is still grounded in what the business earns today. With the focus squarely on profits and the P/E discussion around them, the question is how much of that recent strength can be explained by earnings power rather than sentiment alone. The stock has returned 39.7% over the past year. This puts real pressure on the valuation case to be supported by...",
                "category": "company",
                "datetime": 1790252002,
                "headline": "Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run"
              },
              {
                "id": 142363277,
                "url": "https://finnhub.io/api/news?id=496cc8ecf10d66858d67ac7a5384cf6db78d74d5fa1c838a8812961cba2007b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch. Chris Fenimore, Regeneron’s executive vice",
                "category": "company",
                "datetime": 1790179415,
                "headline": "Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts"
              },
              {
                "id": 142363553,
                "url": "https://finnhub.io/api/news?id=0d4ff5c13a85b2f1c2cccaa7dbfbe35d2b07e1bdecb81874d84b3e806e6da49c",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 10:30 AM...",
                "category": "company",
                "datetime": 1790173792,
                "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript"
              },
              {
                "id": 142356640,
                "url": "https://finnhub.io/api/news?id=d0db740160a2b965b635a57c05836424b88ac56d1b2e2902dfe87a4b0229596b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.",
                "category": "company",
                "datetime": 1790161380,
                "headline": "Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva"
              },
              {
                "id": 142341959,
                "url": "https://finnhub.io/api/news?id=91caa4f0f6201f061d0968441c783b609c494e996ea45d95afcf2e62abdc430e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.",
                "category": "company",
                "datetime": 1790105700,
                "headline": "Is Regeneron Stock a Bargain Below $800?"
              },
              {
                "id": 142360508,
                "url": "https://finnhub.io/api/news?id=5455e32d07068154f9e9850e159061d33863c1d655ac11fe33a82d848aa865d9",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1790075717,
                "headline": "Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years"
              },
              {
                "id": 142335124,
                "url": "https://finnhub.io/api/news?id=05f15544e04a5948690f1b24d39e45c70cf22826c82fe89556909ed1f28c0396",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic",
                "category": "company",
                "datetime": 1790074931,
                "headline": "Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine"
              },
              {
                "id": 142329562,
                "url": "https://finnhub.io/api/news?id=4f5585c2304426aadf3196051b75907a913e7ea668c7a2be7331b40768ce26bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1790065786,
                "headline": "1 S&P 500 Stock Worth Your Attention and 2 We Ignore"
              },
              {
                "id": 142285833,
                "url": "https://finnhub.io/api/news?id=76550e340d05d07bdfae82df5207bff3902bb8f34ed6898882e1c8c942889080",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch",
                "category": "company",
                "datetime": 1789891318,
                "headline": "Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 128,
            "discarded_article_count": 111
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.8,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 717100,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 627590,
              "avg_vol_20": 698490,
              "avg_vol_30": 717100,
              "range_pct_10": 0.10630600402006252,
              "range_pct_20": 0.11332789947312374,
              "range_pct_30": 0.12278937243744417,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8751777994700879,
              "dist_to_20d_high": 0.007436787551653202,
              "down_shrink_days": 4,
              "breakout_level_20d": 813.53003,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.86575899778477
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.8383737761523204,
              "turnoverUsdM": 500.22900273011993,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.REGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 761.6414,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 5.7,
            "take_profit_price": 876.3907,
            "target_multiplier": 2.2,
            "technical_strength": 2.05,
            "take_profit_percent": 8.5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.4973362689959988,
          "stopLossPercent": 5.676747552304641,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 22.9193,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.84
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 107.61
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0404
    },
    "kdj": {
      "d": 69.4,
      "j": 101.77,
      "k": 80.19,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 50.45
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 4474694,
      "recentSlope": 110789.4,
      "previousSlope": -215850
    },
    "rsi": 64.76,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 740.2989,
      "position": "SAR喺價下",
      "distancePct": 8.32,
      "previousTrend": "上升"
    },
    "ma50": 790.7954,
    "macd": {
      "macd": 1.7475097168419325,
      "trend": "強烈看漲",
      "signal": -5.492523890120662,
      "histogram": 7.240033606962594
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 764.415,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 5
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.89,
      "score": 4,
      "avgVolume": 699455,
      "currentVolume": 619494
    },
    "derived": {
      "ma20": 764.0615,
      "ma50": 790.7954,
      "prevClose": 782.04,
      "avgVolume10": 628029,
      "avgVolume20": 699455,
      "changePercent": 3.25,
      "avgVolumeForScore": 699455
    },
    "ma_cross": {
      "ma20": 764.0615,
      "ma50": 790.7954,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 763.8825,
      "prevMa50": 790.8068,
      "spreadPct": 3.38,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 713.4676,
      "upper": 814.6554,
      "position": "上半部"
    },
    "rsi_short": 74.11,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.89
    }
  }
}

{
  "close": 807.48,
  "volume": 619494,
  "changePercent": 3.25
}